All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
On May 25, 2021, positive topline results from the phase III OCEAN study (NCT03151811) of melphalan flufenamide (melflufen) for the treatment of relapsed/refractory multiple myeloma (RRMM) were released. These results demonstrated that melflufen was at least as efficacious as pomalidomide for this indication.1
Based on these data, a supplementary new drug application to move to earlier lines of therapy is planned to be submitted to the FDA in the last quarter of 2021.
EHA 2019 | Updated analysis of the HORIZON phase II trial: Melflufen + dexamethasone for RRMM
This study investigated the efficacy and safety of melflufen and dexamethasone in patients with relapsed or refractory multiple myeloma.
ANCHOR: Melflufen triplet regimens for relapsed/refractory multiple myeloma
At the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Enrique Ocio presented the latest data from the phase I/IIa ANCHOR (OP-104; NCT03481556) study...
Subscribe to get the best content related to multiple myeloma delivered to your inbox